StreetInsider.com News Articles

Plus Therapeutics CNSide assay gains Medical Mutual coverage in Ohio

Tue, 21 Jul 2026 07:30:44 -0400

CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (NASDAQ: PSTV), announced a regional coverage agreement with Medical Mutual, effective July 1, 2026, covering approximately 1.2 million members in Ohio and Kentucky for the CNSide® Cerebrospinal Fluid Tumor Cell Enumeration assay.

The agreement brings the total contracted coverage for the CNSide assay to approximately 127 million people, according to a company statement.

The CNSide® assay is designed to support diagnosis, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The company reports that more than 11,000 tests have been performed at over 120 U.S. cancer institutions since 2020, with the

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Tue, 21 Jul 2026 07:30:00 -0400

HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a regional agreement with Medical Mutual effective July 1, 2026, covering approximately 1.2 million people throughout Ohio and Kentucky, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings CNSide CSF TCE assay total contracted coverage to approximately 127 million people.

The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases.

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Tue, 21 Jul 2026 07:30:00 -0400

The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases.

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Tue, 21 Jul 2026 07:30:00 -0400

The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases.

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Tue, 21 Jul 2026 07:30:00 -0400

The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases.

Plus Therapeutics and Genomic Testing Cooperative to expand CSF platform

Thu, 16 Jul 2026 07:31:00 -0400

Plus Therapeutics, Inc. (Nasdaq: PSTV) and Genomic Testing Cooperative, LCA announced a collaboration to integrate next-generation sequencing (NGS) technology into the CNSide cerebrospinal fluid (CSF) assay platform, according to a press release issued July 16, 2026.

The collaboration is intended to enable DNA and RNA profiling across hundreds of biomarkers from a single CSF specimen, adding a molecular sequencing layer to CNSide's existing circulating tumor cell (CTC) enumeration capability within one CLIA-accredited platform.

The CNSide CSF Tumor Cell Enumeration test received a dedicated AMA PLA code 0640U, effective July 1, 2026, and the CNSide CLIA laboratory is enrolled with Medicare. Commercial payer

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

Thu, 16 Jul 2026 07:30:00 -0400

HOUSTON and LAKE FOREST, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”) and Genomic Testing Cooperative, LCA (“GTC”) today announced a collaboration to integrate GTC’s next-generation sequencing (NGS) technology into the CNSide® cerebrospinal fluid (CSF) assay platform. The collaboration is expected to enable comprehensive DNA and RNA profiling across hundreds of clinically relevant biomarkers from a single CSF specimen, extending CNSide from guideline-recognized CTC enumeration into the guideline-recognized DNA and tumor-derived DNA analytic layer within one integrated platform. The collaboration advances Plus’ three-pillar CNS oncology strategy: targeted radiotherapeutics led by

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

Thu, 16 Jul 2026 07:30:00 -0400

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

Thu, 16 Jul 2026 07:30:00 -0400

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

Thu, 16 Jul 2026 07:30:00 -0400

Plus Therapeutics highlights CNSide role after NCCN guideline update

Tue, 14 Jul 2026 07:32:10 -0400

Plus Therapeutics, Inc. (Nasdaq: PSTV) issued a statement July 14, 2026, noting a recent update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Central Nervous System Cancers, which the company says reinforces the clinical relevance of its CNSide cerebrospinal fluid (CSF) assay platform in leptomeningeal metastases (LM) monitoring.

The updated NCCN guidelines state that CSF analysis remains a standard component of LM diagnosis and that, in patients receiving intrathecal therapy, CSF cytology is typically re-evaluated every four to eight weeks alongside MRI and clinical evaluation.

CNSide is a CSF assay platform developed by CNSide Diagnostics, LLC, a wholly owned

Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

Tue, 14 Jul 2026 07:30:00 -0400

HOUSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), today highlighted the recent update to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Central Nervous System Cancers, including guidance relevant to leptomeningeal metastases (LM), a serious and often underdiagnosed complication of advanced cancer.

The updated NCCN CNS Cancers Guidelines reinforce that cerebrospinal fluid (CSF) analysis remains a standard component of LM diagnosis and disease assessment and that, in patients receiving intrathecal therapy, CSF cytology is typically re-evaluated every four to eight weeks alongside MRI

Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

Tue, 14 Jul 2026 07:30:00 -0400

Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

Tue, 14 Jul 2026 07:30:00 -0400

Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

Tue, 14 Jul 2026 07:30:00 -0400

Form 4 PLUS THERAPEUTICS, INC. For: Jul 01 Filed by: Clowes Howard